Difference between revisions 3939065 and 4107808 on kawiki

{{ვიკი}}{{მანქანური თარგმანი}}
{{Chembox|ImageFileL1=Gamma-thujaplicin.png|ImageSizeL1=125px|ImageAltL1=Skeletal formula of hinokitiol|ImageFileR1=Gamma-Thujaplicin-3D-balls.png|ImageSizeR1=125|ImageAltR1=Ball-and-stick model of the hinokitiol molecule|Verifiedfields=changed|Watchedfields=changed|verifiedrevid=415528328|Reference=<ref>[http://www.sigmaaldrich.com/catalog/ProductDetail.do?N4=469521|ALDRICH&N5=SEARCH_CONCAT_PNO|BRAND_KEY&F=SPEC β-Thujaplicin] at [[Sigma-Aldrich]]</ref>|IUP(contracted; show full)/20200520/pdf/44hzh0v8bqgvlx.pdf "AstiVita - Testing Results for Dr Zinx Zinc + Hinokitiol Combination" (PDF)]. ASX (Australian Stock Exchange). Retrieved 20 May 2020.''</ref> 2020 წლის 18 მაისს დოქტორ ZinX– მა გამოაქვეყნა ტესტის შედეგები „სამედიცინო ნაწილში ვირუსული მოქმედების შესაფასებლად“ რაოდენობრივი შეჩერების ტესტისთვის ”<ref> '''^''' ''Barrett M (18 May 2020). [https://www.drzinx.com/testresults "Dr ZinX Test Results".]
 {{Webarchive|url=https://web.archive.org/web/20200611014014/https://www.drzinx.com/testresults |date=2020-06-11 }} Dr Zinx Oral Spray. Retrieved 20 May 2020.''</ref>   <ref>''Administration, Australian Government Department of Health Therapeutic Goods (2020-05-07). [https://www.tga.gov.au/surrogate-viruses-use-disinfectant-efficacy-tests-justify-claims-against-covid-19 "Surrogate viruses for use in disinfectant efficacy tests to justify claims against COVID-19".] Therapeutic Goods Administration (TGA). Retrieved 2020-05-20.''</ref> 3.25log-ით შემცირებული (99.9% (contracted; show full)wa T, Yonezawa D, Tamura H, Kawabata S, et al. (June 2019). "Antibacterial activity of hinokitiol against both antibiotic-resistant and -susceptible pathogenic bacteria that predominate in the oral cavity and upper airways". Microbiology and Immunology. '''63''' (6): 213–222. doi:[[doi:10.1111/1348-0421.12688|10.1111/1348-0421.12688.]] PMID [https://pubmed.ncbi.nlm.nih.gov/31106894 31106894.]''</ref>

== გამოყენებული ლიტერატურა ==
<references />